The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - FACIT.org
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - FACIT.org
Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
 
Robert J. Motzer
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Camillo Porta
Consulting or Advisory Role - Angelini Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; MSD; Pfizer
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; EUSA Pharma; GE Healthcare; Ipsen; MSD; Novartis; Pfizer
Expert Testimony - EUSA Pharma; Pfizer
Travel, Accommodations, Expenses - Roche
 
Boris Alekseev
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Research Funding - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Eisai; ICON Clinical Research; Janssen; Merck; MSD; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD; Pfizer; Sanofi
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Daiichi Sankyo; Eisai; Indivumed; Ipsen; MSD Oncology
Speakers' Bureau - Eisai; Eisai; Lilly
Research Funding - ASLAN Pharmaceuticals; Bayer; Bristol-Myers Squibb; Eisai; Immunomet; medpacto; MSD Oncology; Roche/Genentech; Sillajen
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - ASCO; Dana Farber Cancer Hospital; KidneyCan; NCCN
Stock and Other Ownership Interests - Pionyr; Tempest Therapeutics
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; IQvia; Janssen Oncology; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); Gateway for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Maria Jose Mendez-Vidal
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Ipsen; Roche
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Pfizer; Roche
 
Sung-Hoo Hong
No Relationships to Disclose
 
Anil Kapoor
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst)
 
Jeffrey C. Goh
Stock and Other Ownership Interests - Immutep
Honoraria - Ipsen
Consulting or Advisory Role - AstraZeneca; Tesaro
Speakers' Bureau - AstraZeneca; Ipsen; Janssen; Mundipharma; Novartis
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca
 
Masatoshi Eto
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Johnson & Johnson; Merck; Ono Pharmaceutical; Pfizer; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Janssen Oncology; Merck; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Takeda (Inst)
 
Jinyi Wang
Research Funding - Eisai (Inst)
 
Janice Pan
Employment - Eisai
 
Alemseged Ayele Asfaw
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Cixin Steven He
Employment - Eisai
 
Kalgi Mody
Employment - Eisai; Eisai
Travel, Accommodations, Expenses - Eisai; Eisai
 
David Cella
No Relationships to Disclose